RNF138 confers cisplatin resistance in gastric cancer cells via activating Chk1 signaling pathway

References

• Zhao L, Pan Y, Gang Y, Wang H, Jin H, Tie J, Xia L, Zhang Y, He L, Yao L, et al. Identification of GAS1 as an epirubicin resistance-related gene in human gastric cancer cells with a partially randomized small interfering RNA library. J Biol Chem. 2009; 284(39): 26273–26285.doi:10.1074/jbc.M109.028068.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu W, Ni P, Li A, Zhou J, Xu S. MiR-99a and MiR-491 Regulate Cisplatin Resistance in Human Gastric Cancer Cells by Targeting CAPNS1. Int J Biol Sci. 2016;12(12):1437–1447. doi:10.7150/ijbs.16529.
   PubMed Web of Science ®Google Scholar
• Abuzeid WM, Jiang X, Shi G, Wang H, Paulson D, Araki K, Jungreis D, Carney J, O’Malley BW Jr., Li D. Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy. J Clin Invest. 2009;119(7):1974–1985. doi:10.1172/JCI33816.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513(7517): 202–209. doi: 10.1038/nature13480.
   PubMed Web of Science ®Google Scholar
• Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265–7279. doi:10.1038/sj.onc.1206933.
   PubMed Web of Science ®Google Scholar
• Mo D, Fang H, Niu K, Liu J, Wu M, Li S, Zhu T, Aleskandarany MA, Arora A, Lobo DN, et al. Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKT-YB1-MDR1. Signaling Pathway Cancer Res. 2016; 76(10): 3057–3066.doi:10.1158/0008-5472.CAN-15-2361.
   PubMed Web of Science ®Google Scholar
• Xu W, Wang S, Chen Q, Zhang Y, Ni P, Wu X, Zhang J, Qiang F, Li A, Roe OD, et al. TXNL1-XRCC1 pathway regulates cisplatin-induced cell death and contributes to resistance in human gastric cancer. Cell Death Dis. 2014;5:(e1055. doi:10.1038/cddis.2014.27.
   Web of Science ®Google Scholar
• Aranda F, Bloy N, Pesquet J, Petit B, Chaba K, Sauvat A, Kepp O, Khadra N, Enot D, Pfirschke C, et al. Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell. Lung Cancer Oncogene. 2015; 34(23): 3053–3062.doi:10.1038/onc.2014.234.
   PubMed Web of Science ®Google Scholar
• Lipinska N, Romaniuk A, Paszel-Jaworska A, Toton E, Kopczynski P, Rubis B. Telomerase and drug resistance in cancer Cell. Mol Life Sci. 2017. doi:10.1007/s00018-017-2573-2.
   PubMed Web of Science ®Google Scholar
• Wilk A, Waligorska A, Waligorski P, Ochoa A, Reiss K. Inhibition of ERbeta induces resistance to cisplatin by enhancing Rad51-mediated DNA repair in human medulloblastoma cell lines. PLoS One. 2012;7(3):e33867. doi:10.1371/journal.pone.0033867.
   PubMed Web of Science ®Google Scholar
• Pouliot LM, Chen YC, Bai J, Guha R, Martin SE, Gottesman MM, Hall MD. Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res. 2012;72(22):5945–5955. doi:10.1158/0008-5472.CAN-12-1400.
   PubMed Web of Science ®Google Scholar
• Duan L, Perez RE, Hansen M, Gitelis S, Maki CG. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1 Cancer. Biol Ther. 2014;15(12):1600–1612. doi:10.4161/15384047.2014.961876.
   Google Scholar
• Zhang D, Piao HL, Li YH, Qiu Q, Li DJ, Du MR, Tsang BK. Inhibition of AKT sensitizes chemoresistant ovarian cancer cells to cisplatin by abrogating S and G2/M arrest. Exp Mol Pathol. 2016;100(3):506–513. doi:10.1016/j.yexmp.2016.05.003.
   PubMed Web of Science ®Google Scholar
• Yarden RI, Metsuyanim S, Pickholtz I, Shabbeer S, Tellio H, Papa MZ. BRCA1-dependent Chk1 phosphorylation triggers partial chromatin disassociation of phosphorylated Chk1 and facilitates S-phase cell cycle arrest. Int J Biochem Cell Biol. 2012;44(11):1761–1769. doi:10.1016/j.biocel.2012.06.026.
   PubMed Web of Science ®Google Scholar
• Chen S, Chen X, Xie G, He Y, Yan D, Zheng D, Li S, Fu X, Li Y, Cdc6 PX. contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells. Oncotarget. 2016;7(26):40362–40376. doi:10.18632/oncotarget.9616.
   PubMed Web of Science ®Google Scholar
• Sen T, Tong P, Stewart CA, Cristea S, Valliani A, Shames DS, Redwood AB, Fan YH, Li L, Glisson BS, et al. CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. Cancer Res. 2017; 77(14): 3870–3884.doi:10.1158/0008-5472.CAN-16-3409.
   PubMed Web of Science ®Google Scholar
• Feng Z, Xu S, Liu M, Zeng YX, Chk1 KT. inhibitor Go6976 enhances the sensitivity of nasopharyngeal carcinoma cells to radiotherapy and chemotherapy in vitro and in vivo. Cancer Lett. 2010;297(2):190–197. doi:10.1016/j.canlet.2010.05.011.
   PubMed Web of Science ®Google Scholar
• Yamada M, Ohnishi J, Ohkawara B, Iemura S, Satoh K, Hyodo-Miura J, Kawachi K, Natsume T, Shibuya H. NARF, an nemo-like kinase (NLK)-associated ring finger protein regulates the ubiquitylation and degradation of T cell factor/lymphoid enhancer factor (TCF/LEF). J Biol Chem. 2006;281(30):20749–20760. doi:10.1074/jbc.M602089200.
   PubMed Web of Science ®Google Scholar
• Xu L, Lu Y, Han D, Yao R, Wang H, Zhong S, Luo Y, Han R, Li K, Fu J, et al. Rnf138 deficiency promotes apoptosis of spermatogonia in juvenile male mice. Cell Death Dis. 2017; 8(5): e2795.doi:10.1038/cddis.2017.110.
   PubMedGoogle Scholar
• Han D, Liang J, Lu Y, Xu L, Miao S, Lu LY, Song W, Wang L. Ubiquitylation of Rad51d Mediated by E3 Ligase Rnf138 Promotes the Homologous Recombination Repair Pathway. PLoS One. 2016;11(5):e0155476. doi:10.1371/journal.pone.0155476.
   PubMed Web of Science ®Google Scholar
• Giannini AL, Gao Y, Bijlmakers MJ. T-cell regulator RNF125/TRAC-1 belongs to a novel family of ubiquitin ligases with zinc fingers and a ubiquitin-binding domain. Biochem J. 2008;410(1):101–111. doi:10.1042/BJ20070995.
   PubMedGoogle Scholar
• Zhou YX, Chen SS, Wu TF, Ding DD, Chen XH, Chen JM, Su ZP, Li B, Chen GL, Xie XS, et al. A novel gene RNF138 expressed in human gliomas and its function in the glioma cell line U251. Anal Cell Pathol (Amst). 2012; 35(3): 167–178.doi:10.3233/ACP-2011-0051.
   PubMedGoogle Scholar
• Ismail IH, Gagne JP, Genois MM, Strickfaden H, McDonald D, Xu Z, Poirier GG, Masson JY, Hendzel MJ. The RNF138 E3 ligase displaces Ku to promote DNA end resection and regulate DNA repair pathway choice. Nat Cell Biol. 2015;17(11):1446–1457. doi:10.1038/ncb3259.
   PubMed Web of Science ®Google Scholar
• Yard BD, Reilly NM, Bedenbaugh MK, Pittman DL. RNF138 interacts with RAD51D and is required for DNA interstrand crosslink repair and maintaining chromosome integrity DNA Repair. Amst. 2016;42:.82–93. doi:10.1016/j.dnarep.2016.04.006.
   Google Scholar
• Schmidt CK, Galanty Y, Sczaniecka-Clift M, Coates J, Jhujh S, Demir M, Cornwell M, Beli P, Jackson SP. Systematic E2 screening reveals a UBE2D-RNF138-CtIP axis promoting DNA repair. Nat Cell Biol. 2015;17(11):1458–1470. doi:10.1038/ncb3260.
   PubMed Web of Science ®Google Scholar
• Matsuoka S, Ballif BA, Smogorzewska A, Rd MDE, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal Y. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007;316(5828):1160–1166. doi:10.1126/science.1140321.
   PubMed Web of Science ®Google Scholar
• Huang D, Duan H, Huang H, Tong X, Han Y, Ru G, Qu L, Shou C, Zhao Z. Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition. Sci Rep. 2016;6(20502). doi: 10.1038/srep20502.
   Google Scholar
• Wu Q, Vasquez KM. Human MLH1 protein participates in genomic damage checkpoint signaling in response to DNA interstrand crosslinks, while MSH2 functions in DNA repair. PLoS Genet. 2008;4(9):e1000189. doi:10.1371/journal.pgen.1000189.
   PubMed Web of Science ®Google Scholar
• Zhang YH, Wu Q, Xiao XY, Li DW, Wang XP. Silencing MRP4 by small interfering RNA reverses acquired DDP resistance of gastric cancer cell. Cancer Lett. 2010;291(1):76–82. doi:10.1016/j.canlet.2009.10.003.
   PubMed Web of Science ®Google Scholar
• Marechal A, Li JM, Ji XY, Wu CS, Yazinski SA, Nguyen HD, Liu S, Jimenez AE, Jin J, Zou L. PRP19 transforms into a sensor of RPA-ssDNA after DNA damage and drives ATR activation via a ubiquitin-mediated circuitry . Mol Cell. 2014;53(2):235–246. doi:10.1016/j.molcel.2013.11.002.
   PubMed Web of Science ®Google Scholar
• Ivanova T, Zouridis H, Wu Y, Cheng LL, Tan IB, Gopalakrishnan V, Ooi CH, Lee J, Qin L, Wu J, et al. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Gut. 2013; 62(1): 22–33. doi:10.1136/gutjnl-2011-301113.
   PubMed Web of Science ®Google Scholar
• Xie X, Lozano G, Siddik ZH. Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53. Oncogene. 2016;35(36):4798–4806. doi:10.1038/onc.2016.12.
   PubMed Web of Science ®Google Scholar
• Wang Q, Chen Q, Zhu L, Chen M, Xu W, Panday S, Wang Z, Li A, Røe OD, Chen R, et al. JWA regulates TRAIL-induced apoptosis via MARCH8-mediated DR4 ubiquitination in cisplatin-resistant gastric cancer cells. Oncogenesis. 2017; 6(7): e353.doi:10.1038/oncsis.2017.57.
   PubMedGoogle Scholar